Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European …
S Cesaro, P Ljungman, M Mikulska, HH Hirsch… - Leukemia, 2022 - nature.com
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel virus that spread
worldwide from 2019 causing the Coronavirus disease 19 (COVID-19) pandemic. SARS …
worldwide from 2019 causing the Coronavirus disease 19 (COVID-19) pandemic. SARS …
[HTML][HTML] COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies
SARS-CoV-2 is the virus responsible for the COVID-19 pandemic. COVID-19 has highly
variable disease severity and a bimodal course characterized by acute respiratory viral …
variable disease severity and a bimodal course characterized by acute respiratory viral …
[HTML][HTML] An immune-based biomarker signature is associated with mortality in COVID-19 patients
Immune and inflammatory responses to severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) contribute to disease severity of coronavirus disease 2019 (COVID-19) …
(SARS-CoV-2) contribute to disease severity of coronavirus disease 2019 (COVID-19) …
A neutrophil activation signature predicts critical illness and mortality in COVID-19
Pathologic immune hyperactivation is emerging as a key feature of critical illness in COVID-
19, but the mechanisms involved remain poorly understood. We carried out proteomic …
19, but the mechanisms involved remain poorly understood. We carried out proteomic …
Emerging aspects of cytokine storm in COVID-19: The role of proinflammatory cytokines and therapeutic prospects
COVID-19 has claimed millions of lives during the last 3 years since initial cases were
reported in Wuhan, China, in 2019. Patients with COVID-19 suffer from severe pneumonia …
reported in Wuhan, China, in 2019. Patients with COVID-19 suffer from severe pneumonia …
Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review …
M Tagliamento, E Agostinetto, M Bruzzone… - Critical reviews in …, 2021 - Elsevier
Background A systematic review and meta-analysis was performed to estimate mortality in
adult patients with solid or hematological malignancies and SARS-CoV-2 infection. Methods …
adult patients with solid or hematological malignancies and SARS-CoV-2 infection. Methods …
Current state and future opportunities in granulocyte colony-stimulating factor (G-CSF)
H Link - Supportive Care in Cancer, 2022 - Springer
Granulocyte colony-stimulating factor (G-CSF), a protein that stimulates the growth of new
blood cells, was isolated from human cells by Malcolm Moore and Karl Welte in 1984 [1]. It …
blood cells, was isolated from human cells by Malcolm Moore and Karl Welte in 1984 [1]. It …
[HTML][HTML] Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus
C Buske, M Dreyling, A Alvarez-Larrán, J Apperley… - ESMO open, 2022 - Elsevier
Background The COVID-19 pandemic has created enormous challenges for the clinical
management of patients with hematological malignancies (HMs), raising questions about …
management of patients with hematological malignancies (HMs), raising questions about …
Immunomodulatory effects of G-CSF in cancer: Therapeutic implications
KA Mouchemore, RL Anderson - Seminars in immunology, 2021 - Elsevier
Numerous preclinical studies have reported a pro-tumour role for granulocyte colony-
stimulating factor (G-CSF) that is predominantly mediated by neutrophils and MDSCs, the …
stimulating factor (G-CSF) that is predominantly mediated by neutrophils and MDSCs, the …
ELF5 is a potential respiratory epithelial cell-specific risk gene for severe COVID-19
Despite two years of intense global research activity, host genetic factors that predispose to
a poorer prognosis of COVID-19 infection remain poorly understood. Here, we prioritise …
a poorer prognosis of COVID-19 infection remain poorly understood. Here, we prioritise …